Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M111Revenue $M11.5Net Margin (%)-126.0Altman Z-Score-10.0
Enterprise Value $M67.0EPS $-0.2Operating Margin %-134.3Piotroski F-Score4
P/E(ttm)--Beneish M-Score-1.8Pre-tax Margin (%)-126.0Higher ROA y-yY
Price/Book3.310-y EBITDA Growth Rate %-12.8Quick Ratio3.4Cash flow > EarningsN
Price/Sales9.25-y EBITDA Growth Rate %-14.3Current Ratio3.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-25.5Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-38.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M62.9ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ARQL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARQLFirst Eagle Investment 2015-06-30 Add0.01%$1.53 - $2.26
($1.93)
$ 1.64-15%Add 52.45%8,719,968
ARQLFirst Eagle Investment 2015-03-31 Add0.01%$1.1 - $2.46
($1.59)
$ 1.643%Add 28.69%5,719,968
ARQLFirst Eagle Investment 2014-12-31 Add$1.06 - $1.36
($1.18)
$ 1.6439%Add 56.31%4,444,899
ARQLGeorge Soros 2014-09-30 Sold Out $1.12 - $1.56
($1.31)
$ 1.6425%Sold Out0
ARQLGeorge Soros 2014-06-30 Buy $1.34 - $2.04
($1.56)
$ 1.645%New holding78,600
ARQLFirst Eagle Investment 2013-09-30 Reduce-0.01%$2.15 - $2.79
($2.51)
$ 1.64-35%Reduce -26.47%3,314,553
ARQLFirst Eagle Investment 2012-12-31 Add0.01%$2.18 - $2.95
($2.6)
$ 1.64-37%Add 49.46%4,539,651
ARQLFirst Eagle Investment 2012-06-30 Add0.01%$5.53 - $8.16
($6.56)
$ 1.64-75%Add 28.79%2,673,589
ARQLGeorge Soros 2011-12-31 Sold Out -0.0014%$4.58 - $6.05
($5.55)
$ 1.64-70%Sold Out0
ARQLGeorge Soros 2011-09-30 Add$4.11 - $6.64
($5.2)
$ 1.64-68%Add 54.79%16,100
ARQLFirst Eagle Investment 2011-03-31 Add0.03%$5.85 - $6.95
($6.41)
$ 1.64-74%Add 84.22%1,693,456
ARQLGeorge Soros 2011-03-31 Buy $5.85 - $6.95
($6.41)
$ 1.64-74%New holding12,200
ARQLFirst Eagle Investment 2010-12-31 Add0.01%$4.95 - $6.14
($5.53)
$ 1.64-70%Add 29.43%919,266
ARQLFirst Eagle Investment 2010-03-31 Reduce-0.02%$3.04 - $3.92
($3.45)
$ 1.64-52%Reduce -56.47%685,266
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARQL is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ARQL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LOBERG MICHAEL DDirector 2015-12-17Buy3,719$2.16-24.07view
LOBERG MICHAEL DDirector 2015-12-16Buy1,231$2.14-23.36view
Pucci PaoloCEO 2015-12-15Buy1,283$2.16-24.07view
Pucci PaoloCEO 2015-12-11Buy1,108$2.1-21.9view
ZENNER PATRICK JDirector 2015-12-11Buy2,300$2.15-23.72view
Pucci PaoloCEO 2015-12-10Buy7,609$2.1-21.9view
ZENNER PATRICK JDirector 2015-03-11Buy10,625$2.32-29.31view
Pucci PaoloCEO 2014-11-20Buy5,000$1.2630.16view
ZENNER PATRICK JDirector 2014-11-14Buy20,830$1.236.67view
Messenger William GDirector 2014-11-14Buy8,500$1.2135.54view

Quarterly/Annual Reports about ARQL:

    News about ARQL:

    Articles On GuruFocus.com
    Jean-Marie Eveillard Increases Stakes in Cancer Therapeutics Company Arqule Inc May 05 2015 
    Jean-Marie Eveillard Adds to Stake in Arqule Inc. May 03 2015 
    ArQule Inc. Reports Operating Results (10-Q) Nov 09 2010 
    ArQule Inc. Reports Operating Results (10-Q) Aug 04 2010 
    ArQule Inc. Reports Operating Results (10-Q) May 06 2010 
    ArQule Inc. (ARQL) CEO Paolo Pucci buys 5,000 Shares Nov 13 2009 
    ArQule Inc. Reports Operating Results (10-Q) Aug 07 2009 
    ArQule Inc. (ARQL) CEO Paolo Pucci buys 2,500 Shares May 15 2009 
    ArQule Inc. Reports Operating Results (10-Q) May 08 2009 

    More From Other Websites
    ArQule to Present at Upcoming Investor Conferences Feb 04 2016
    ArQule Provides Proprietary Pipeline Update for AKT Inhibitors Jan 28 2016
    ArQule Presents Clinical Biomarker Data From Phase 2 Study and Ongoing Phase 3 METIV-HCC Study of... Jan 25 2016
    12 Biotechs With Binary Events Coming This Year Jan 08 2016
    ArQule, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 24 2015
    ArQule upgraded by RBC Capital Mkts Dec 21 2015
    ArQule Announces Orphan Drug Designation in Cholangiocarcinoma and Clinical Update for ARQ 087 Dec 15 2015
    ArQule Announces Orphan Drug Designation in Cholangiocarcinoma and Clinical Update for ARQ 087 Dec 15 2015
    ArQule and Daiichi Sankyo Announce Completion of Accrual in METIV-HCC Phase 3 Trial of Tivantinib... Dec 10 2015
    ArQule and Daiichi Sankyo Announce Completion of Accrual in METIV-HCC Phase 3 Trial of Tivantinib... Dec 10 2015
    ARQULE INC Financials Dec 08 2015
    Do Hedge Funds Love Hugoton Royalty Trust (HGT)? Nov 27 2015
    ArQule's Drug Gets Orphan Drug Status for Proteus Syndrome Nov 18 2015
    ArQule and the National Human Genome Research Institute of the National Institutes of Health... Nov 17 2015
    UPDATE -- ArQule Presents Data on Tivantinib and Proprietary Pipeline at AACR-NCI-EORTC Conference Nov 09 2015
    ArQule Presents Data on Tivantinib and Propietary Pipeline at AACR-NCI-EORTC Conference Nov 09 2015
    Edited Transcript of ARQL earnings conference call or presentation 4-Nov-15 2:00pm GMT Nov 04 2015
    ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 04 2015
    ArQule Reports Third Quarter 2015 Financial Results Nov 04 2015
    ArQule reports 3Q loss Nov 04 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK